Despite no difference in event-free survival found between short and long preoperative chemo, long preoperative significantly increased CA19-9 response rate, N0 resection rate, number of the ...
IMFINZI® (durvalumab)-basedregimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial More than two thirds of patients treated with ...
Positive results from the TROPION-Breast02 phase 3 trial showed DATROWAY ® (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary ...
Nivolumab plus ipilimumab significantly improves OS and PFS in NSCLC compared to chemotherapy, with a 30% reduction in death risk and no significant heterogeneity observed. Amivantamab plus lazertinib ...
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today noted that our partner, Akeso, Inc. ("Akeso," HKEX Code: 9926.HK) published results from the Phase III HARMONi-A trial, ...
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback